Related Experiment Video
Updated: Jun 13, 2025
10:31
Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture
Published on: April 8, 2016
14.5K
IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network
Pushkar Aggarwal1, Alan B Fleischer1
1Department of Dermatology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
Journal of Clinical Medicine
|September 14, 2024
Summary
Interleukin-17 (IL-17) and IL-23 inhibitors offer the quickest onset of action for plaque psoriasis. These systemic therapies, including bimekizumab, demonstrate faster meaningful clinical responses compared to other treatments.
Area of Science:
- Dermatology
- Pharmacology
- Clinical Trials
Background:
- Plaque psoriasis has multiple systemic treatment options with varied mechanisms of action.
- Determining the speed of therapeutic response is crucial for patient management.
Purpose of the Study:
- To compare the time to onset of action for various systemic therapies used in plaque psoriasis treatment.
- To identify which treatments provide the fastest meaningful clinical response.
Main Methods:
- A network meta-analysis of randomized controlled trials (RCTs) involving treatments for moderate to severe plaque psoriasis.
- Calculation of weighted average time to achieve Psoriasis Area and Severity Index 75% (PASI75) and PASI90 improvement.
- Statistical comparison to determine significant differences in time to response.
Main Results:
- IL-17 inhibitors demonstrated the shortest time to PASI75 and PASI90 in weighted mean analysis.
- In meta-analysis, bimekizumab, brodalumab, and ixekizumab showed the fastest time to PASI75.
- Bimekizumab was significantly faster for PASI75 and PASI90 compared to other therapeutics.
- Several IL-17 and IL-23 inhibitors showed rapid onset for PASI90 without significant differences among them.
Conclusions:
- IL-17 and IL-23 inhibitors are associated with the shortest time to meaningful clinical response in plaque psoriasis.
- Treatment decisions should balance the speed of onset with individual drug safety profiles.
Related Concept Videos
01:24T Cell Types and Functions
961
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
961
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120